Literature DB >> 1599491

Inhibition of HIV-1 integration protein by aurintricarboxylic acid monomers, monomer analogs, and polymer fractions.

M Cushman1, P Sherman.   

Abstract

Several aurintricarboxylic acid (ATA) monomers, monomer analogs, and polymer fractions have been tested as inhibitors of HIV-1 integration protein (IN). Both of the ATA monomers and all of the ATA polymer fractions inhibited a selective DNA cleavage reaction catalyzed by IN. The ATA monomer analogs were inactive or had low activity. The activities of the substances as inhibitors of HIV IN correlated in a positive way with their activities as inhibitors of the cytopathic effect of HIV-1 in CEM and HIV-2 in MT4 cells. These results suggest that inhibition of HIV IN may contribute to the antiviral activity of the ATA monomers and monomer analogs in cell culture.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1599491     DOI： 10.1016/s0006-291x(05)80958-1

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  19 in total

1.  Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules.

Authors:  C M Farnet; B Wang; J R Lipford; F D Bushman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

2.  Inhibitors of HIV-1 replication [corrected; erratum to be published] that inhibit HIV integrase.

Authors:  W E Robinson; M G Reinecke; S Abdel-Malek; Q Jia; S A Chow
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

3.  Effects of mutations in residues near the active site of human immunodeficiency virus type 1 integrase on specific enzyme-substrate interactions.

Authors:  J L Gerton; S Ohgi; M Olsen; J DeRisi; P O Brown
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism.

Authors:  C M Farnet; B Wang; M Hansen; J R Lipford; L Zalkow; W E Robinson; J Siegel; F Bushman
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

5.  Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase.

Authors:  B McDougall; P J King; B W Wu; Z Hostomsky; M G Reinecke; W E Robinson
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

6.  Equivalent inhibition of half-site and full-site retroviral strand transfer reactions by structurally diverse compounds.

Authors:  D Hazuda; P Felock; J Hastings; B Pramanik; A Wolfe; G Goodarzi; A Vora; K Brackmann; D Grandgenett
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

7.  Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action.

Authors:  Roberto Di Santo; Roberta Costi; Alessandra Roux; Marino Artico; Antonio Lavecchia; Luciana Marinelli; Ettore Novellino; Lucia Palmisano; Mauro Andreotti; Roberta Amici; Clementina Maria Galluzzo; Lucia Nencioni; Anna Teresa Palamara; Yves Pommier; Christophe Marchand
Journal:  J Med Chem       Date:  2006-03-23       Impact factor: 7.446

8.  Inhibitors of human immunodeficiency virus integrase.

Authors:  M R Fesen; K W Kohn; F Leteurtre; Y Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

9.  Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.

Authors:  R A Puras Lutzke; N A Eppens; P A Weber; R A Houghten; R H Plasterk
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

10.  Inhibition of human immunodeficiency virus integrase by bis-catechols.

Authors:  R L LaFemina; P L Graham; K LeGrow; J C Hastings; A Wolfe; S D Young; E A Emini; D J Hazuda
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.